Loading clinical trials...

Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19 | Clinical Trials | Clareo Health

UNKNOWNNCT04397588

Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19

The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to re...

Lead sponsor: Rennes University Hospital•44 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Cécile Ferragu

CONTACT

0299282555 [email protected]

DRI

CONTACT

0299282555 [email protected]

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment300

Start dateApr 2020

Last updatedAug 31, 2020

Condition

Acute Refractory Heart Failure Related to SARS-CoV 2

Locations shown

Angers University Hospital

Angers

Besançon Hospital

Besançon

Brest university Hospital

Brest

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 31, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions